{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2"},{"groupId":"OG001","value":"74.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"495"},{"groupId":"OG001","value":"496"}],"units":"Participants"}],"description":"Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For \"Lapatinib + Capecitabine\" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as \\>/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.","groups":[{"description":"Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.","id":"OG000","title":"Trastuzumab Emtansine"},{"description":"Participants received lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 mg/m\\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Participants of this group were allowed to cross over to receive trastuzumab emtansine based on statistically significant OS benefit in favor of trastuzumab emtansine demonstrated in second interim analysis.","id":"OG001","title":"Lapatinib + Capecitabine"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants on the basis of the treatment assigned at randomization.","reportingStatus":"POSTED","timeFrame":"From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)","title":"Percentage of Participants With Treatment Failure","type":"SECONDARY","unitOfMeasure":"percentage of participants"}